Last updated: February 19, 2026
Hydrocortisone butyrate is a topical corticosteroid prescribed for inflammatory skin conditions. The drug is manufactured and sold by multiple pharmaceutical companies worldwide. The following details key suppliers, their product offerings, and market distribution.
Major Suppliers and Manufacturing Companies
| Company Name |
Country of Origin |
Product Focus |
Market Presence |
Regulatory Status |
| Mitsubishi Tanabe Pharma |
Japan |
Topical corticosteroids, including hydrocortisone butyrate |
Asia, global licensing |
Approved by PMDA, FDA, EMA |
| Almirall |
Spain |
Dermatology products, including corticosteroid creams |
Europe, Latin America |
EMA approval, FDA registration |
| Teva Pharmaceutical Industries |
Israel |
Generic corticosteroids and dermatology drugs |
North America, Europe, Latin America |
FDA, EMA approvals |
| Sandoz (Novartis) |
Switzerland |
Generic formulations, including hydrocortisone butyrate |
Global |
Regulatory approval in multiple jurisdictions |
| Dr. Reddy's Laboratories |
India |
Topical corticosteroid products |
India, Southeast Asia, Africa |
DCGI approved, various international approvals |
| Pfizer |
United States |
Dermatology products, some corticosteroid formulations |
North America, Europe |
FDA, EMA approvals |
| Astellas Pharma |
Japan |
Focus on skin medications including corticosteroids |
Japan, Asia |
PMDA approved |
Market Distribution and Product Forms
Hydrocortisone butyrate is available in various forms:
- Creams (0.1%, 0.2%)
- Ointments (0.1%, 0.2%)
- Lotions (less common)
- Gel formulations (market-dependent)
Primary markets include Europe, North America, and Asia. Licensing agreements frequently distribute the drug beyond original manufacturers' territories, expanding availability.
Regulatory and Patent Status
- Original patents for hydrocortisone butyrate formulations have expired in most jurisdictions, leading to generic availability.
- Regulatory approvals typically align with national health authorities' standards (FDA in the US, EMA in Europe, PMDA in Japan).
- Some formulations face patent restrictions or exclusivity periods, impacting market entry timing for generics.
Key Considerations for Procurement
- Suppliers differ in geographic focus and regulatory approval status.
- Some manufacturers focus on proprietary formulations, while others offer generics.
- Market-specific formulations and concentrations vary to meet local regulations and clinical needs.
Summary
Multiple global companies supply hydrocortisone butyrate. Original manufacturers include Mitsubishi Tanabe Pharma and Almirall, with a broad landscape of generic producers such as Teva, Sandoz, Dr. Reddy's, Pfizer, and Astellas. The product's availability is driven by regulatory approvals, patent status, and regional distribution agreements.
Key Takeaways
- Hydrocortisone butyrate is supplied by both original developers and generics producers worldwide.
- Major suppliers operate in Asia, Europe, North America, and emerging markets.
- Product availability includes creams, ointments, and gels in varying concentrations.
- Regulatory approvals vary, impacting market access and competition.
- Expiration of key patents has increased generic market penetration.
FAQs
1. Are hydrocortisone butyrate formulations interchangeable across suppliers?
Variations in concentration, formulation type, and manufacturing quality mean not all products are directly interchangeable without physician approval.
2. Which countries have the largest market for hydrocortisone butyrate?
The US, European Union, and Japan have the highest demand due to well-established dermatology markets and regulatory approval.
3. How do patent statuses affect the availability of hydrocortisone butyrate generics?
Patent expirations in most jurisdictions have led to increased generic options, lowering prices and expanding access.
4. Can I source hydrocortisone butyrate directly from manufacturers?
Procurement generally occurs through authorized distributors or wholesalers, with direct sourcing limited to large-scale healthcare institutions.
5. What should buyers consider when selecting a hydrocortisone butyrate supplier?
Regulatory approval, product quality, pricing, supply reliability, and regional distribution rights are key factors.
References
- European Medicines Agency. (2022). Product information for dermatological corticosteroids. EMA.
- Food and Drug Administration. (2021). Approved dermatology drugs. FDA.
- Japanese Pharmaceuticals and Medical Devices Agency. (2022). List of approved dermatological medications. PMDA.
- Novartis. (2021). Product portfolio overview — Sandoz dermatology products.
- Reuters. (2022). Global market analysis for topical corticosteroids.
